Clinical trial
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
NCT00108836 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2005
- Completion date
- May 31, 2006
- Enrollment
- 400
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.